{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "DJ-1",
        "Protein_Change": {
          "ref": "P",
          "alt": "L166P",
          "position": "166"
        },
        "variant_string_id": "DJ-1 P166L"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states DJ-1 mutations are recessive and associated with early-onset Parkinson's disease (PD), with L166P destabilizing the protein.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links L166P to PD through protein destabilization, aligning with the disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Proteasome inhibition was used to rescue protein levels in L166P, a cell phenotype rescue assay.",
          "judgment": "Yes",
          "reasoning": "The assay (proteasome inhibition) is applicable to model protein stability and function, matching the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Proteasome inhibition was effective for L166P, with partial rescue, indicating functional impact.",
          "judgment": "Yes",
          "reasoning": "The assay (proteasome inhibition) was valid, showing reduced protein levels, supporting pathogenicity."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No explicit OddsPath calculation, but the assay showed reduced protein levels, indicating functional impact.",
          "judgment": "Yes",
          "reasoning": "The assay (proteasome inhibition) demonstrated reduced protein levels, aligning with PS3 thresholds for pathogenicity."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "L166P shows moderate pathogenicity due to reduced protein levels via proteasome inhibition, aligning with ACMG guidelines."
    },
    {
      "variant_id": {
        "Gene": "DJ-1",
        "Protein_Change": {
          "ref": "A",
          "alt": "M26I",
          "position": "26"
        },
        "variant_string_id": "DJ-1 A26I"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "M26I is described as unstable but less dramatic, with no explicit link to PD.",
          "judgment": "Yes",
          "reasoning": "The mutation is associated with reduced protein stability but not disease manifestation, aligning with benign criteria."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "No valid assay controls for M26I, as the effect was less dramatic.",
          "judgment": "No",
          "reasoning": "Insufficient controls for M26I, making it difficult to assess pathogenicity."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "No valid assay controls for M26I, as the effect was less dramatic.",
          "judgment": "No",
          "reasoning": "Insufficient data to validate the assay, preventing pathogenicity assessment."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No OddsPath calculation, but the mutation is described as less dramatic.",
          "judgment": "No",
          "reasoning": "Insufficient data to determine pathogenicity, classifying as benign."
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_supporting"
      },
      "overall_conclusion": "M26I is classified as benign due to insufficient evidence of functional impact and lack of valid assay controls."
    },
    {
      "variant_id": {
        "Gene": "DJ-1",
        "Protein_Change": {
          "ref": "A",
          "alt": "R98Q",
          "position": "98"
        },
        "variant_string_id": "DJ-1 A98Q"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "R98Q is described as stable and not associated with PD.",
          "judgment": "Yes",
          "reasoning": "The mutation is stable and not linked to disease, aligning with benign criteria."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "No valid assay controls for R98Q, as the effect was not dramatic.",
          "judgment": "No",
          "reasoning": "Insufficient controls for R98Q, making it difficult to assess pathogenicity."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "No valid assay controls for R98Q, as the effect was not dramatic.",
          "judgment": "No",
          "reasoning": "Insufficient data to validate the assay, preventing pathogenicity assessment."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No OddsPath calculation, but the mutation is described as stable.",
          "judgment": "No",
          "reasoning": "Insufficient data to determine pathogenicity, classifying as benign."
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_supporting"
      },
      "overall_conclusion": "R98Q is classified as benign due to stable mutation and lack of valid assay controls."
    }
  ]
}